熱門資訊> 正文
Itamar Medical’s WatchPAT300 OK'd in Japan
2020-10-01 18:45
Itamar Medical(NASDAQ:ITMR)announces that its flagship WatchPAT300 Home Sleep Apnea Testing (HSAT) device has been granted PMDA approval for use in the Japanese market, effective September 14, 2020.
The WatchPAT300 will be made available in Japan through Philips Japan Co., ITMR's exclusive Japanese distributor.
FDA-approved WatchPAT is used for diagnosing Sleep Apnea at patients home.
Click to subscribe to real-time analytics on ITMR
Now read:Beam Therapeutics prices equity offering at $23.50 »
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
